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INTRODUCTION
Cushing’s disease is characterized by adrenal hypersecretion
of glucocorticoids secondary to overproduction of adrenocor-
ticotrophic hormone (ACTH) by a corticotroph adenoma in
the pituitary gland. Apart from iatrogenic Cushing’s syndro-
me, Cushing’s disease is the most common cause of hypercor-
tisolism, comprising approximately 70% of all such cases (1).
The incidence of Cushing’s disease is estimated to be 0.7 to
2.4 cases per million people per year. The disease occurs more
commonly in women than in men (1, 2). In the majority of
cases, ACTH-secreting pituitary adenomas are small (less than
10 mm in diameter) and confined within the sella turcica.
However, 4-10% of patients present with larger tumors (more
than 10 mm in diameter) (3). These larger tumors sometimes
cause symptoms due to mass effect before there are full-blown
endocrine manifestations.
For patients with corticotroph adenomas, the set point of
ACTH suppressibility to glucocorticoids is altered, and larg-
er amounts of exogenous glucocorticoids are necessary to sup-
press plasma ACTH levels. Therefore, pituitary corticotroph
adenomas are characterized by blunting of cortisol feedback
to low-dose dexamethasone testing, but the plasma ACTH
levels are suppressible with administration of high dose dex-
amethasone (4). However, it has been reported that cortico-
troph macroadenomas are often associated with higher ACTH
levels and less glucocorticoid suppressibility on high-dose dex-
amethasone administration, whether assessment is performed
through measurement of urinary free cortisol excretion or th-
rough serum cortisol levels (5, 6). Moreover, it has also been
reported that macroadenomas are more refractory to surgical
treatment and show a more unfavorable prognosis than micro-
adenomas (7, 8).
The aim of this study was to compare the clinical and bio-
chemical characteristics of Cushing’s disease patients with
corticotroph macroadenomas with those of patients with mi-
croadenomas.
MATERIALS AND METHODS
This study included 30 patients (5 male, 25 female; mean age
38.7 yr [range: 13-73 yr]) with pituitary-dependent ACTH-
secreting adenomas. All patients were diagnosed at Samsung
Medical Center between 1996 and 2006. Of the 30 patients,
23 (76.7%) were diagnosed with pituitary corticotroph micro-
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Comparisons between Macroadenomas and Microadenomas in
Cushing’ s Disease: Characteristics of Hormone Secretion and Clinical
Outcomes
It has been suggested that the patients with Cushing’s disease secondary to pitu-
itary macroadenomas (>10 mm) have higher basal adrenocorticotropic hormone
(ACTH) levels, which are less suppressible on high-dose dexamethasone suppres-
sion tests (HDDST). We compared the clinical and biochemical characteristics of
patients with macroadenomas (N=7) and microadenomas (N=23) who were diag-
nosed at Samsung Medical Center in Korea between 1996 and 2006. Basal morn-
ing plasma ACTH levels were 101.5±23.2 pg/mL for macroadenoma patients and
83.6±11.1 pg/mL for microadenoma patients (mean±SEMs) (p=0.44). Morning
serum cortisol levels were 26.8±3.2 μ g/dL for macroadenoma patients and 29.5
±2.9 μ g/dL for microadenoma patients (p=0.77). The proportion of patients who
showed suppressibility on HDDST was almost identical in the two groups (71.4%
[5/7] for macroadenoma patients vs. 72.7% [16/22] for microadenoma patients,
p=1.00). Furthermore, the remission rate with trans-sphenoidal surgery was simi-
lar between the two groups (100% [5/5] for macroadenoma patients vs. 73.3% [11/
15] for microadenoma patients, p=0.53). Thus, tumor size is not a major determi-
nant of hormone secretion or clinical outcomes in patients with Cushing’s disease.
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adenomas, and the remaining 7 patients (23.3%) were diag-
nosed with macroadenomas by sella magnetic resonance imag-
ing (MRI). None of the macroadenoma patients was male, and
5 of the 23 microadenoma patients were male.
The diagnosis of Cushing’s disease was based on charac-
teristic signs and symptoms, laboratory findings, sella MRI,
inferior petrosal sinus samplings (IPSS), and histopathology.
Hormonal assays were performed according to standardized
clinical procedures. At entry into the study, all patients were
admitted to the hospital, whereupon their basal plasma ACTH
and serum cortisol concentrations were measured at 0800h
to 0900h. Most patients (26/30) had their urine collected for
24 hr to determine the 24-hr urinary free cortisol, along with
the urine creatinine. Dynamic tests were done for all patients.
That is, all but one patient underwent the high-dose dexam-
ethasone suppression tests (HDDST), and the remaining pa-
tient underwent the corticotropin-releasing hormone (CRH)
stimulation test. The HDDST was performed using one of the
following methods: 1) oral administration of 2 mg of dexam-
ethasone every 6 hr for 2 days (N=25); 2) suppression of the
serum cortisol during 7 hr of intravenous dexamethasone ad-
ministration (N=5); or 3) 8mg overnight dexamethasone sup-
pression test (N=1). The serum and urine cortisol levels after
HDDST were defined as “responsive” if the serum values fell
by more than 50% of the baseline and if the urine values fell
by more than 90% of the baseline. Biochemical assays were
also used to measure the preoperative basal levels of hGH,
IGF-1, TSH, free or total T4, FSH, LH, and prolactin. Twen-
ty patients underwent preoperative combined pituitary stim-
ulation testing, principally those in the macroadenoma group.
IPSS was performed before and after administration of CRH
stimulation in 17 patients with Cushing’s disease because ei-
ther their MRI findings showed no definite mass with gadolin-
ium enhancement or their biochemical tests were equivocal.
Sampling of the plasma ACTH levels was performed at base-
line and at 1, 3, 5, 10, 15, and 30 min after intravenous ovine
CRH (0.1 mg) injection. An increased ratio (>2) of the infe-
rior petrosal:peripheral vein sample at baseline and a peak
inferior petrosal:peripheral vein ACTH ratio of ≥3 after CRH
injection confirmed the presence of an ACTH-secreting pitu-
itary tumors. IPSS demonstration of a right-to-left venous
ACTH gradient of less than 0.7 or greater than 1.4 was con-
sidered to represent a lateralization to the left or right, respec-
tively.
Surgical modalities for treating Cushing’s disease included
endoscopic trans-sphenoidal surgery (TSA) (N=22), stereo-
tactic gamma knife surgery (N=6), and open craniotomy
(N=1); one patient was lost to follow-up without receiving
any treatment. If patients were not cured by their initial treat-
ment, then they underwent a second treatment using exter-
nal radiation therapy (N=1) or gamma knife surgery (N=4).
All but one patient underwent TSA by a single surgeon through
trans-septal or endonasal access. If the tumor was identified
by preoperative MRI or in the operation field, then gross total
tumor removal was performed. If the tumor was not localized
on the preoperative MRI, but IPSS showed an ACTH level
gradient, the first exploration was made on the side with the
higher ACTH gradient. If no tumor was identified upon
exploring the entire gland, then partial hemihypophysecto-
my was performed either on the side that showed ACTH
dominance on IPSS testing or on the side where tumor was
likely to exist as determined by intraoperative frozen biopsy.
Gamma knife surgery was indicated in case where the lesion
was not amenable to TSA, such as in case of intrasellar or cav-
ernous invasion.
Basal ACTH and cortisol levels were measured on postop-
erative day 2 in all patients who underwent TSA; some pati-
ents underwent repeat basal hormone sampling within 1 week
after operation. Patients were assessed for clinical remission
at 6 months after TSA, with remission defined as being free
of symptoms caused by excessive glucocorticoid hormone and
either 1) dependency on glucocorticoid substitutions or 2)
biochemical eucortisolemia (morning serum cortisol from 6
to 26 μ g/dL) without hormone replacement. Among the pa-
tients who underwent TSA (N=22), 20 patients were followed
for at least 6 months (range: 10 to 101 months, mean 41 mo-
nths). Persistent Cushing’s disease was defined as failure to
fulfill the biochemical criteria for remission at 6 months after
the first operation and along with necessity of a second inter-
vention. Relapse was defined as recurrence of clinical signs
and symptoms in the presence of basal serum cortisol levels
increased above the upper limit of normal and non-suppress-
ibility of cortisol on low dose dexamethasone suppression test-
ing (0.5 mg of dexamethasone every 6 hr for 2 days).
Statistical analysis was performed using SPSS 13.0 for Win-
dows (SPSS, Inc., Chicago, IL, U.S.A.). Data are depicted as
means±SEMs for continuous variables and as percents for
dichotomous variables. The mean differences between macro-
adenomas and microadenomas were compared using the Mann-
Whitney test, and differences between the observed frequen-
cies were compared using Fisher’s exact test. Comparisons with
pvalues less than 0.05 were considered statistically significant.
RESULTS
At baseline, the mean ages of patients with macroadenomas
and microadenomas were 35.7±3.7 and 39.6±3.3 yr, respec-
tively (means±SEMs) (p=0.74). Five of 30 patients were male,
and all of them had microadenomas. There were no clinical
signs or symptoms that differentiated macroadenomas from
microadenomas before sella MRI was performed, including
visual field defects (data not shown). Fifty-three percent of
all patients (52% [12/23]microadenoma vs. 57% [4/7]macro-
adenoma) were diagnosed with obesity, which was defined as
a body mass index (BMI) more than 25 kg/m2. Fifty percent
of all patients (43% [10/23]microadenoma vs. 71% [5/7]ma-
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tory or on fasting plasma glucose levels equal to or greater
than 126 mg/dL on admission. Characteristically, the major-
ity of patients (83%, 25/30) had high blood pressure, with
a statistically significant difference between the groups (96%
[22/23]microadenoma vs. 43% [3/7]macroadenoma, p=0.006)
(data not shown).
Early morning basal plasma ACTH and serum cortisol lev-
els were available for all patients; the urine free cortisol level
was measured in 26 patients. Although patients with macro-
adenomas showed a tendency to have higher ACTH levels,
there was no statistically significant difference between the
two groups (101.5±23.2 pg/mL for macroadenomas vs. 83.6
±11.1 pg/mL for microadenomas, p=0.44). Serum cortisol
and urine free cortisol levels also showed no statistically signif-
icant difference. Moreover, there was no linear correlation be-
tween maximal tumor diameter and preoperative basal ACTH,
cortisol, and urine free cortisol levels (data not shown). With
regard to the cortisol to ACTH ratio, which is the degree of
cortisol secretion for a given ACTH level, there was no sta-
tistically significant difference between the two groups (0.31
±0.05 for macroadenomas vs. 0.47±0.09 for microadeno-
mas, p=0.21) (Table 1).
After high dose dexamethasone administration, 72.4% (21/
29) of patients showed suppressibility. However, there was no
difference between the two groups with regard to the percent-
age of patients that manifested suppression (71.4% [5/7] for
macroadenoma patients vs. 72.7% [16/22] for microadenoma
patients, p=1.00) or with regard to the magnitude of suppres-
sion (65.6±11.2% for macroadenoma patient vs. 65.9±5.3
% for microadenoma patients, p=0.82) (Table 2). Of the 21
patients with microadenomas who were followed for at least
6 months, 15 patients underwent TSA, and the remaining
6 patients underwent gamma knife surgery. There was no
statistically significant difference in long-term remission rates
between the two groups (73.3% for TSA [11/15] vs. 100%
[6/6] for gamma knife surgery, p=0.28) (data not shown).
Among the patients who underwent TSA (N=22), one mi-
croadenoma patient and one macroadenoma patient were ex-
cluded from the analysis because their follow-up periods were
not sufficient to determine their remission status. Clinical and
biochemical remission was observed in 16 of 20 patients (80%),
including 11 of 15 microadenoma patients (73.3%) and all
macroadenoma patients (5/5) (Table 2). Among the four
patients with non-remission, three patients never achieved
remission status. That is, they had persistent Cushing’s dis-
ease; one patient relapsed 28 months after the first operation.
To elucidate differences between patients in the remission
group and patients in the non-remission group, we compared
The data is expressed as means±SEM for continuous variables and as
numbers (%) for the dichotomous variables.




Age (yr) 35.7±3.7 39.6±3.3 0.74
Gender (male/female) 0/7 5/18 0.30
Hypokalemia (%) 2 (28.6) 9 (39.1) 1.00
Basal plasma ACTH level 101.5±23.2 83.6±11.1 0.44
(pg/mL)
Basal serum cortisol level 26.8±3.2 29.5±2.9 0.77
(μ g/dL)
Basal cortisol/ACTH ratio 0.31±0.05 0.47±0.09 0.21
Basal 24 hr urine free 2,080.2±997.5 1,312.6±416.8 0.32
cortisol (μ g/day/Cr)
Table 1. Comparisons of the baseline characteristics and basal
hormone levels between patients with macroadenomas and pa-
tients with microadenomas
The data is expressed as means±SEM for continuous variables and as
numbers (%) for the dichotomous variables.
*Complete tumor removal was defined as no residual tumor mass on the
postoperative sella MRI and positive ACTH immunoreactivity in the tumor
cells; 
� The postoperative basal hormone levels were measured within 1
week after TSA.
HDDST, high-dose dexamethasone suppression test; TSA, trans-sphe-




No of macroadenoma (%) 5/16 (31.3) 0/4 (0.0) 0.53
Basal plasma ACTH level 90.2±17.0 84.2±5.7 0.49
(pg/mL)
Basal serum cortisol level 29.4±3.7 33.3±6.8 0.68
(μ g/dL)
No of suppression with 10/15 (66.7) 3/4 (75.0) 1.00
HDDST (%)
No of complete tumor 9/14 (64.3) 1/4 (25.0) 0.28
removal (%)*
Postoperative basal plasma 16.9±3.7 21.6±6.6 0.44
ACTH level (pg/mL)
�
Postoperative basal serum 8.6±3.6 14.3±5.9 0.06
cortisol level (μ g/dL)
�
Table 3. Comparison of the baseline characteristics and post-
operative hormone levels according to the treatment outcome
with TSA
The data is expressed as means±SEM for the continuous variables and
as numbers (%) for the dichotomous variables.





No of suppression with 5/7 (71.4) 16/22 (72.7) 1.00
HDDST (%)
% of suppression with 65.6±11.2 65.9±5.3 0.82
HDDST
No of long-term remission 5/5 (100) 11/15 (73.3) 0.53
with TSA (%)
Table 2. Response to HDDST and the treatment outcomes be-
tween macroadenomas and microadenomasthe baseline and immediate postoperative hormone levels in
the two groups. There were no differences between the preop-
erative basal ACTH and cortisol levels of the groups (ACTH:
90.2±17.0 pg/mL in the remission group vs. 84.2±5.7 pg/
mL in the non-remission group, p=0.49; cortisol: 29.4±3.7
μ g/dL in the remission group vs. 33.3±6.8 μ g/dL in the non-
remission group, p=0.68). We found no differences in the pre-
operative HDDST suppressibility between the remission group
and the non-remission group (66.7% [10/15] for the remis-
sion group vs. 75.0% [3/4] for the non-remission group, p=
1.00) (Table 3). Although the postoperative plasma ACTH
levels did not show a statistical difference between the two
groups, the serum cortisol level, which was measured with-
in one week after TSA, revealed a marginal difference between
the remission group and the non-remission group (8.6±
3.6 μ g/dL for the remission group vs. 14.3±5.9 μ g/dL for
the non-remission group, p=0.06) (Table 3).
We then determined if tumor mass still remained after oper-
ation, with complete tumor removal defined as no residual
tumor mass on postoperative sella MRI and positive ACTH
immunoreactivity in the tumor cells. Although no statistical-
ly significant difference was observed between the two groups,
patients in the remission group tended to have complete tumor
removal on imaging and biopsy, as compared with the non-
remission group (64.3% [9/14] for the remission group vs.
25.0% [1/4] for the non-remission group, p=0.28) (Table 3).
DISCUSSION
In this study, 7 (22.6%) out of the 30 patients with Cush-
ing’s disease had macroadenomas. Although we took into ac-
count that our institution is a large tertiary center, the pro-
portion of the patients with macroadenoma was somewhat
higher than that of the previous reports. According to the re-
port by the survey committee for endocrine disease in Kore-
an Endocrine Society, out of the 87 patients with Cushing’s
disease, nine patients (10.3%) had macroadenomas (9). How-
ever, it was also reported that the true prevalence of Cushing’s
disease that’s caused by corticotroph macroadenomas has been
underestimated and the actual number maybe reach approx-
imately 20% of all patients with Cushing’s disease (10).
Previous studies have suggested that Cushing’s disease ca-
used by macroadenomas showed higher levels of basal ACTH
and cortisol, and less suppressibility with high dose dexam-
ethasone suppression testing as compared with microadeno-
mas (5, 6). Woo et al. reported that the plasma ACTH and
serum cortisol levels were significantly higher in the mac-
roadenoma group than those in the microadenoma group
(3). However, the cortisol-to-ACTH ratio showed relatively
lower levels of cortisol for a given ACTH level in the macro-
adenoma group. Thus, they speculated that this was caused
by the lowered biological activity of ACTH in the patients
with macroadenoma because the ACTH assay that was used
cross-reacts with the ACTH precursor POMC. Consequent-
ly, the proportion of the biologically active form of ACTH
was lowered with the immunoassay that they used. Actually,
Gibson et al. proposed that macroadenomas were poorly dif-
ferentiated and had impaired processing of POMC to ACTH;
moreover, they preferentially secrete the biologically inactive
precursors of ACTH that could interfere with ACTH mea-
surements and the secretion of which is not regulated like
that of ACTH (11).
However, our results did not show any significant differ-
ences of the basal plasma ACTH, serum cortisol or the urine
free cortisol levels between microadenomas and macroade-
nomas. Moreover, there were no linear correlations between
the maximal tumor diameter and the ACTH, cortisol and
urine free cortisol levels. We offer the following explanations
for our results. First, our ACTH assay does not cross-react with
POMC; therefore it was unlikely that the plasma ACTH lev-
els in our results were falsely increased by biologically inac-
tive ACTH precursors. Therefore, the cortisol to ACTH ratio
was not lower in the macroadenoma group in our study. Sec-
ond, although it did not reach statistical significance, the basal
ACTH level in the macroadenoma group showed a tenden-
cy to be higher as compared with the microadenoma group.
However, there was a wide range of the ACTH levels and there
was considerable overlap between the groups, so it was diffi-
cult to predict whether the patient would be in the macroade-
noma group or the microadenoma group with examining the
preoperative ACTH levels. Third, it seems that the biologi-
cal behavior and clinical outcomes of Cushing’s disease were
not determined by tumor size, and the cutoff point of 10 mm
that divided the Cushing’s disease into macroadenomas and
microadenomas was thought to be somewhat arbitrary as is
the case for thyroid carcinoma. 
It was reported that macroadenomas showed more aggres-
sive clinical behaviors and they were more refractory to treat-
ments than microadenomas (7, 8). However, in our study,
the long-term remission rate with TSA was not low for the
macroadenoma patients and moreover, all five patients with
macroadenoma were successfully treated by their first opera-
tion (73.3% [11/15] vs. 100% [5/5] for microadenomas and
macroadenomas, respectively, p=0.53). The results of Pereira
et al. are in accordance with our findings and they reported
that although macroadenomas showed a tendency for delayed
normalization of the serum cortisol level compared with
microadenomas, the long-term cure rate of macroadenomas
was not different from that of microadenomas (12). Also,
the remission rate of Cushing’s disease was higher in mac-
roadenomas compared with microadenomas by the report
from Korean Endocrine Society (32.7% [18/55] vs. 57.1%
[4/7] for microadenomas and macroadenomas, respectively)
(9). Instead, it seems that the surgical outcome was critically
determined by complete surgical removal of the tumor mass
rather than by the size of the mass. For the patients with mic-
roadenoma, 4 patients out of 16 were not cured after their
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first operation and they underwent an additional treatment
modality. Among these four patients, all but one of these
patients had a tumor mass that was poorly localized on the
preoperative sella MRI and/or operation field, and it was
difficult to accurately remove the tumor mass. Although it
did not reach statistical significance, the patients with remis-
sion showed a tendency of complete tumor removal, which
was defined as no residual tumor mass on postoperative sella
MRI and positive ACTH immunoreactivity in the tumor
cells, as compared with the non-remission group (Table 3).
The definition of a biochemical cure of Cushing’s disease
has been the subject of much controversy (7, 12-16). A vari-
ety of criteria have been used to assess the postoperative dis-
ease status. Some investigators have advocated performing
provocative tests such as an over-night low-dose dexametha-
sone suppression test (17) or a CRH stimulation test (18), and
other investigators have used non-provocative tests such as
measuring the basal ACTH and cortisol levels or the 24-hr
urine free cortisol concentration (12, 15); moreover, these tests
were assessed at different time points, respectively. Rees et al.
have proposed a more stringent requirement of a postopera-
tive serum cortisol level of <1.8 μ g/dL within 1 week after
TSA as a definition of remission; with using this criterion,
they reported a remission rate of 77% during a median of 6
yr follow-up (14). However, it appears that this value of less
than 1.8 μ g/dL of serum cortisol is too strict and some patients,
who are in long-term remission, were above this threshold
at their immediate postoperative periods. Indeed, in the pre-
sent study, out of the 16 patients with remission, only five
patients (31.3%) met this strict definition of less than 1.8 μ g/
dL of serum cortisol. Also, although the number of patients
was limited, the post-operative serum cortisol level, which was
measured within 1 week after TSA, was different between the
remission group and the non-remission group (8.6±3.6 μ g/
dL vs. 14.3±5.9 μ g/dL for the remission and non-remission
groups, respectively, p=0.06). Therefore, somewhat higher
immediate postoperative serum cortisol levels can be allowed
to predict long-term remission, as compared with the values
proposed by the previous reports. Actually, about one third
of the patients with remission (5/14) showed a serum cortisol
level of more than 5.0 μ g/dL within 1 week after operation.
The main limitation of the present study was that the num-
ber of patients with macroadenoma was relatively small. There-
fore, further studies are needed to confirm the biologic behav-
ior and long-term prognosis of Cushing’s disease according
to the size of the tumor mass.
In conclusion, the pituitary Cushing’s disease that was
caused by macroadenomas was not different on the biochem-
ical tests from the disease that was caused by microadenomas,
including the basal hormone levels and the suppressibility
with HDDST. Moreover, the clinical outcomes of TSA also
showed no difference between the two groups. Instead, it
appears that the surgical outcome was dependent on accu-
rate tumor localization and complete mass removal.
REFERENCES
1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s
syndrome. Lancet 2006; 367: 1605-17.
2. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen
U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P,
Schmidt K, Weeke J. Incidence and late prognosis of cushing’s syn-
drome: a population-based study. J Clin Endocrinol Metab 2001; 86:
117-23.
3. Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I, Jenk-
ins PJ, Monson JP, Besser GM, Grossman AB. Clinical and biochemi-
cal characteristics of adrenocorticotropin-secreting macroadenomas.
J Clin Endocrinol Metab 2005; 90: 4963-9.
4. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and
differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s
states. Endocr Rev 1998; 19: 647-72.
5. Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte
ET, Hsu DW, Zervas NT, Swearingen B, Sleeper M, Klibanski A.
Biochemical assessment of Cushing’s disease in patients with cortico-
troph macroadenomas. J Clin Endocrinol Metab 1998; 83: 1619-23.
6. Selvais P, Donckier J, Buysschaert M, Maiter D. Cushing’s disease:
a comparison of pituitary corticotroph microadenomas and macroade-
nomas. Eur J Endocrinol 1998; 138: 153-9.
7. Blevins LS Jr, Christy JH, Khajavi M, Tindall GT. Outcomes of
therapy for Cushing’s disease due to adrenocorticotropin-secreting
pituitary macroadenomas. J Clin Endocrinol Metab 1998; 83: 63-7.
8. Cannavo S, Almoto B, Dall’Asta C, Corsello S, Lovicu RM, De Menis
E, Trimarchi F, Ambrosi B. Long-term results of treatment in patients
with ACTH-secreting pituitary macroadenomas. Eur J Endocrinol
2003; 149: 195-200.
9. The Korean Society of Endocrinology. The Survey Committee for
Endocrine Disease in Korea. The incidence and clinical character-
istics of Cushing’s disease in Korea. J Kor Endocrinol Soc 2000; 15:
31-45.
10. Bochicchio D, Losa M, Buchfelder M. Factors influencing the imme-
diate and late outcome of Cushing’s disease treated by transsphenoidal
surgery: a retrospective study by the European Cushing’s Disease
Survey Group. J Clin Endocrinol Metab 1995; 80: 3114-20.
11. Gibson S, Ray DW, Crosby SR, Dornan TL, Jennings AM, Bevan
JS, Davis JR, White A. Impaired processing of proopiomelanocortin
in corticotroph macroadenomas. J Clin Endocrinol Metab 1996; 81:
497-502.
12. Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR,
Smit JW, Roelfsema F, Romijn JA. Long-term predictive value of
postsurgical cortisol concentrations for cure and risk of recurrence
in Cushing’s disease. J Clin Endocrinol Metab 2003; 88: 5858-64.
13. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan
ET, Bell S, Rahl R, Lu A, Wilson CB. Transsphenoidal microsurgery
for Cushing’s disease: initial outcome and long-term results. J Clin
Endocrinol Metab 2004; 89: 6348-57.
14. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF.
Long-term follow-up results of transsphenoidal surgery for Cushing’s
disease in a single centre using strict criteria for remission. Clin En-
docrinol (Oxf) 2002; 56: 541-51.Cushing’s Disease and Tumor Size 51
15. Rollin GA, Ferreira NP, Junges M, Gross JL, Czepielewski MA. Dy-
namics of serum cortisol levels after transsphenoidal surgery in a
cohort of patients with Cushing’s disease. J Clin Endocrinol Metab
2004; 89: 1131-9.
16. Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang
C, Swerdloff RS, Kelly DF. Clinical review: early morning cortisol
levels as a predictor of remission after transsphenoidal surgery for
Cushing’s disease. J Clin Endocrinol Metab 2006; 91: 7-13.
17. Findling JW, Raff H, Aron DC. The low-dose dexamethasone sup-
pression test: a reevaluation in patients with Cushing’s syndrome. J
Clin Endocrinol Metab 2004; 89: 1222-6.
18. Nishizawa S, Oki Y, Ohta S, Yokota N, Yokoyama T, Uemura K.
What can predict postoperative “endocrinological cure” in Cushing’s
disease? Neurosurgery 1999; 45: 239-44.